News
-
![]()
Aspire Biopharma, Inc. Completes Stability Study of Sublingual Aspirin Product Test Formulation
HUMACAO, PR, June 21, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that as a material part of its Development Agreement and partnership with Glatt Air Techniques, Inc. (“Glatt”), it has successfully completed a six- month the stability and solubility study of its aspirin-based sublingual aspirin product. Working…
-
![]()
Aspire Biopharma, Inc. Announces Newly Appointed Board of Directors Members
HUMACAO, PR, May 25, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the election results and appointment of two new Board of Directors members effective Thursday, May 25, 2023. On Thursday, May 25, 2023, the shareholders of Aspire Biopharma, Inc., in a unanimous vote,…
-
![Aspire Biopharma]()
Aspire Biopharma, Inc. and Glatt Air Techniques, Inc. Scientists Create Test Batch of Sublingual Aspirin Product
HUMACAO, PR, November 11 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that through its Development agreement and in connection with domain expert scientists from Glatt Air Techniques, Inc. (“Glatt”), Aspire and Glatt has completed the development of a “test batch” of its aspirin-based sublingual aspirin product. Working…
-
![]()
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, July 7, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has entered a pharmaceutical product Development Agreement with Glatt Air Techniques, Inc. (“Glatt”). The Development Agreement solidifies our strong partnership with Glatt, a world-class manufacturing firm specializing in pharmaceutical and other industries, for scientific…
-
![]()
Aspire Biopharma, Inc. Continues to Build a World-Class Team
HUMACAO, PR, May 17, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of Nancy Taylor, Esq., to its highly skilled team of professional advisors. Aspire Biopharma, Inc. is excited to announce securing an engagement with Nancy Taylor, Esq., the Chair of the…
-
![]()
Aspire Biopharma, Inc. Continues to Build a World Class Team
HUMACAO, PR, May 4, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of Michael Shuster, Esq., to its highly skilled team of professional advisors. Aspire Biopharma, Inc. is excited to announce securing the engagement of Michael Shuster, Esq., partner in the Life…
-
![]()
Aspire Biopharma, Inc. Acquires Technology Assets from Instaprin Pharmaceuticals, Inc.
HUMACAO, PR, March 28, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the acquisition of the intellectual property assets (“IP”) of Instaprin Pharmaceuticals, Inc.(“Instaprin”). The acquisition of Instaprin Pharmaceuticals’ intellectual property assets includes bringing groundbreaking drug delivery technology to the Aspire portfolio. In the transaction, Aspire acquired the…
